ABBV-CLS-628 / AbbVie, Calico Life Sciences - LARVOL DELTA

Safety and Tolerability of ABBV-CLS-628: Results From a Phase 1 First-in-Human Study (ERA 2025) - No abstract available

Clinical • P1 data • Chronic Kidney Disease • Nephrology • Renal Disease

A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (clinicaltrials.gov) - P2 | N=240 | Not yet recruiting | Sponsor: AbbVie

Adverse events • New P2 trial • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease